Trial Profile
A Randomized, Double Blind, Phase I/II Trial of Low-Dose Interlekin-2 Immunotherapy in Established Type 1 Diabetes
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 22 Nov 2023
Price :
$35
*
At a glance
- Drugs Aldesleukin (Primary)
- Indications Type 1 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms PROREG
- 15 Nov 2023 Planned End Date changed from 1 Oct 2025 to 1 Dec 2028.
- 15 Nov 2023 Planned primary completion date changed from 1 Aug 2025 to 1 Dec 2026.
- 15 Nov 2023 Planned initiation date changed from 1 Dec 2021 to 1 Jun 2023.